October 22, 2015

JDS Therapeutics, Nutrition21 Complete 1$6 Million Series Round B Of Institutional Equity Financing

JDS Therapeutics, LLC (“JDS”), a privately-held specialty pharmaceutical company and its Nutrition 21 LLC nutritional ingredient subsidiary, announced today that it has closed a $16 million Series B institutional equity financing round led by 1315Capital, a Philadelphia-based investment firm specializing in healthcare..

more news

MORE NEWS
Get in Touch

500 Mamaroneck AveSuite 510Harrison, NY 10528

Nutrition21 Proudly Supports the Following Industry Associations

N21 New Footer Image V2 Uai Nutrition21

©2022 Nutrition21, LLC. All rights reserved.       

Nitrosigine®, Velositol®, nooLVL®, Lustriva®, Chromax®, Zinmax®, and their associated logos are registered trademarks of Nutrition21, LLC.  All third party trademarks are the property of their respective owners. Nutrition21, LLC's products are protected by a number of patents including, but not limited to: US Patent Nos. 6,809,115; 6,803,456; 7,576,132; 8,062,677; 8,933,022; 9,028,879; 9,119,835; 9,597,404; 9,675,702; 10,183,049; and 10,245,325.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.